Results 131 to 140 of about 35,812 (218)

Proteomic profiling identifies candidate biomarkers for small intestinal neuroendocrine tumours G1 and G2

Journal of Neuroendocrinology, Volume 38, Issue 10, October 2026.
Abstract Although small intestinal neuroendocrine tumours (SI‐NET) Grade 1 (G1) and 2 (G2) are often studied together, clinical course and response to treatment may differ. We hypothesized that these tumour groups express different markers in blood that may inform future treatment strategies. Blood from 107 SI‐NET patients (G1 n = 64, G2 n = 43) and 50
Malin Grönberg, Dimitrios Papantoniou, Eva Tiensuu Janson   +2 more
wiley   +1 more source

RUNX1T1 drives stem-like small-cell neuroendocrine prostate cancer identity. [PDF]

Front Cell Dev Biol
Wang Z, Jung H, Hong C, Chen N, Jo Y, Jung I, Kim T, Lee G, Chien K, Chen M, Huang J, Park JW.   +11 more
europepmc   +1 more source

Exploring the Anticancer Potential of Schiff Base Complexes: A Mini‐Review

ChemMedChem, Volume 21, Issue 17, 14 September 2026.
Schiff base metal complexes as promising anticancer agents: highlighting DNA interactions, cytotoxicity, molecular targets, and mechanisms of cancer cell death. Schiff bases are well known for their ability to form stable coordination compounds with several transition metals, making them valuable for medicinal chemistry purposes.
Atif Ahmad, Anam, Marcos V. Palmeira‐Mello, Sabir Khan, José Clayston Melo Pereira   +4 more
wiley   +1 more source

Urethral Metastasis of Therapy-Induced Neuroendocrine Prostate Cancer Successfully Managed With Chemoradiotherapy: A Case Report. [PDF]

IJU Case Rep
Kayaba T, Washino S, Hayase T, Yazaki K, Saito K, Miyagawa T.   +5 more
europepmc   +1 more source

A stress-adaptive lipid kinase axis defines metabolic vulnerabilities in neuroendocrine prostate cancer. [PDF]

Cancer Cell
Zheng Y, Cheng C, Cao Y, Cruz G, Zhang Y, Paturu R, Mahapatra S, Hu J, Mannan R, Karabürk H, Bhattacharyya R, Yin Y, Zhao Y, Liu W, Cao X, Xue H, Li C, Wang Z, Miner SJ, Reichert ZR, Mehra R, Vaishampayan U, Sahai V, Weisman LS, Ding K, Lyssiotis CA, Wang Y, Chinnaiyan AM, Qiao Y.   +28 more
europepmc   +1 more source

The Prognostic Role of the Lung Immune Prognostic Index in Neuroendocrine Prostate Cancer: A Multicenter Retrospective Study. [PDF]

Diagnostics (Basel)
Turan M, Baser MN, Ozkaya Kutluay F, Unlu A, Kutlu O, Cakıroglu U, Aydin AA, Unal OU, Gokoz Dogu G, Oktay E.   +9 more
europepmc   +1 more source

Mechanistic insights and molecular therapy for neuroendocrine prostate cancer. [PDF]

Front Oncol
Niu Y, Zhang S, Zhang S, Tao J, Zhu Y.
europepmc   +1 more source

A Case of De Novo Neuroendocrine Prostate Cancer Presenting With Elevated Carcinoembryonic Antigen (CEA) Levels. [PDF]

Cureus
Tazawa S, Ishibashi Y, Hashimoto Y.
europepmc   +1 more source

A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer. [PDF]

J Exp Med
Nunes de Almeida F, Vasciaveo A, Giacobbe A, Di Bernardo M, Zou M, Antao AM, de Brot S, Rodriguez-Calero A, Chui A, Wang ALE, Floc'h N, Kim JY, Park S, Afari SN, Mukhammadov T, Ortega N, Josyula SS, Arriaga JM, Wang J, Lu J, Shen MM, Rubin MA, Califano A, Abate-Shen C.   +23 more
europepmc   +1 more source

Glutamate Ionotropic Kainate Receptors as Therapeutic Targets in Enzalutamide-Resistant and Neuroendocrine Prostate Cancer. [PDF]

Int J Mol Sci
Qu H, Xu P, Yang JC, Wei F, Zhao J, Wang L, Corey E, Mitsiades N, Lam K, Iczkowski KA, Li Y, Gao AC, Dall'Era M, Liu C.   +13 more
europepmc   +1 more source